Home › Diffuse Large B-Cell Lymphoma › Pennsylvania › Philadelphia
Diffuse Large B-Cell Lymphoma clinical trials in Philadelphia, PA
15 studies for Diffuse Large B-Cell Lymphoma are looking for participants at sites in and around Philadelphia (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
RecruitingPhase 2
- Fox Chase Cancer Center, Philadelphia
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RecruitingObservational study
- Children's Hospital of Philadelphia, Philadelphia
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
RecruitingPhase 2
- Thomas Jefferson University Hospital, Philadelphia
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
RecruitingPhase 2/3
- Alliance Cancer Specialists (ACS) ( Site 8001), Horsham · 16 mi away
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
RecruitingPhase 2
- Abramson Cancer Center and Perelman Center for Advanced Medicine ( Site 0131), Philadelphia
- Temple University Hospital ( Site 0133), Philadelphia
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RecruitingPhase 1
- University of Pennsylvania Abramson Cancer Center, Philadelphia
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
RecruitingPhase 1/2
- Children's Hospital of Philadelphia (CHOP) ( Site 1021), Philadelphia
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
RecruitingPhase 1/2
- Thomas Jefferson University, Philadelphia
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
RecruitingPhase 1/2
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
RecruitingPhase 1
- University of Pennsylvania / Abramson Cancer Center, Philadelphia
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
RecruitingPhase 1
- University of Pennsylvania, Abramson Cancer Center, Philadelphia
Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas
RecruitingPhase 1
- Abramson Cancer Center, University of Pennsylvania, Philadelphia
Epcoritamab-CAR T Cells for Large B-cell Lymphomas
RecruitingPhase 2
- Abramson Cancer Center at the University of Pennsylvania, Philadelphia
SynKIR-310 for Relapsed/Refractory B-NHL
RecruitingPhase 1
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
RecruitingPhase 2
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
Diffuse Large B-Cell Lymphoma trials in other cities
- New York City, NY21 studies
- Baldwin Park, CA19 studies
- Chicago, IL18 studies
- Los Angeles, CA17 studies
- Houston, TX17 studies
- Boston, MA16 studies
- Milwaukee, WI16 studies
- Nashville, TN15 studies
- Portland, OR15 studies
- Durham, NC14 studies
- Dallas, TX13 studies
- Seattle, WA12 studies
Other studies in Philadelphia
- Cancer (all types)59 studies
- Breast Cancer56 studies
- Non-Small Cell Lung Cancer51 studies
- Metastatic Cancer46 studies
- Colorectal Cancer44 studies
- Ovarian Cancer44 studies
- Prostate Cancer44 studies
- Lung Cancer36 studies
- Acute Myeloid Leukemia34 studies
- Heart Failure31 studies
- Endometrial Cancer28 studies
- Depression26 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.